Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

Author: BearyJohn F, BenhamouClaude-Laurent, BoonenSteven, BurgioDavid E, DelmasPierre D, EusebioRachelle A, ManZulema, MatzkinEllen, McClungMichael R, RacewiczArtur, RouxChristian, ZanchettaJosé R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, double-blind, multi-center study compared the efficacy and safety of a single 150 mg monthly dose of risedronate to a 5 mg daily dose for treating postmenopausal osteoporosis.
Paper Details　
Original Abstract of the Article :
Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. This randomized, double-blind, multi-center study was designed to assess the efficacy and safety of a single 150 mg risedronate on...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bone.2007.09.001

データ提供：米国国立医学図書館（NLM）

Risedronate: A Powerful Ally in the Fight Against Osteoporosis

This study dives into the treatment of [postmenopausal osteoporosis] using [risedronate]. The researchers investigated the efficacy and safety of [a single 150 mg risedronate once-a-month oral dose] compared to a more frequent regimen. This research sheds light on the potential benefits and safety of a convenient once-a-month dose of risedronate.

A Convenient Approach: Risedronate Once a Month

This study suggests that a single 150 mg dose of risedronate once a month is as effective as a daily regimen in treating postmenopausal osteoporosis. This finding may be a welcome relief for patients who prefer a less frequent dosing schedule. The study highlights the importance of discussing potential risks and benefits with your doctor before starting any new medication.

Strengthening Bones in the Shifting Sands of Time

This study offers valuable information for women facing postmenopausal osteoporosis. Remember, the desert of aging can be a harsh landscape, but with proper care and treatment, we can find strength and stability. It's crucial to listen to your body and consult with your doctor to find the most suitable treatment plan for your unique needs.

Dr.Camel's Conclusion

This study, "Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis," evaluated the efficacy and safety of a single 150 mg risedronate dose once a month compared to a daily regimen. The study found that both regimens were effective, suggesting that a once-a-month dosing schedule could be a convenient option for patients.

Date :
  1. Date Completed 2008-04-03
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17920005

DOI: Digital Object Identifier

10.1016/j.bone.2007.09.001

Related Literature

Article Analysis
・Side Effects of risedronate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.